38.53 0.00 (0.00%)
After hours: 4:24PM EDT
|Bid||38.55 x 1800|
|Ask||38.56 x 1200|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|Beta (3Y Monthly)||0.94|
|PE Ratio (TTM)||46.99|
|Earnings Date||May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||42.11|
Stock pickers are generally looking for stocks that will outperform the broader market. And while active stock picking involves risks (and requires diversification) it can also provide excess returns. For example, the QI...
Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]
QIAGEN N.V. plans as previously announced to release its report on results for the first quarter 2019 on Monday, May 6 at approximately 22:05 Central European Time / 16:05 Eastern Standard Time .
Novel therascreen® FGFR RGQ RT-PCR Kit will aid in identifying patients eligible for treatment with BALVERSA™ , developed by Janssen
Frankfurt Prime Standard: QIA) today announced that its modern gold standard QuantiFERON®-TB test for detection of latent tuberculosis (TB) infections has surpassed 60 million tests administered, having impacted the lives of millions of patients worldwide and supporting the global fight against this public health issue. QIAGEN is continuing to improve and innovate with new automation options for the fourth-generation QuantiFERON®-TB Gold Plus (QFT®-Plus) test which will continue to drive rapid growth in the conversion of latent TB testing from the century-old technology of tuberculin skin tests to QIAGEN’s modern, accurate and efficient blood test.
NeuMoDx plans to deliver 11 CE-IVD assays to QIAGEN by the end of 2019 on NeuMoDx System as part of aggressive menu expansion plans, including blood-borne viruses, women’s health a
Frankfurt Prime Standard: QIA) today announced new data of the QIAstat-Dx Meningitis / Encephalitis panel. The preliminary data demonstrates effective detection of the most prevalent central nervous system pathogens with high analytical sensitivity and specificity levels, including the discrimination of clinically relevant strains and subtypes. This new test will expand the QIAGEN menu of diagnostic panels for syndromic testing, adding to CE-IVD marked DiagCORE tests for respiratory and gastrointestinal infections that were launched in 2018.
Qiagen NV NYSE:QGENView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for QGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding QGEN is favorable, with net inflows of $116.60 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
LabCorp's (LH) wide exposure in the companion diagnostics space further enhances QIAGEN's personalized health collaborations with the pharmaceutical bigwigs.
Frankfurt Prime Standard: QIA) today announced a master service agreement with LabCorp® (LH) to further accelerate the access of cancer patients to QIAGEN’s companion diagnostic products following regulatory approvals of drugs and their associated tests. As a new participant in QIAGEN’s Day-One Lab Readiness program, LabCorp will be able to provide physicians and patients with faster access to new, genomically targeted drugs that are becoming increasingly important therapies for a growing variety of cancers.
AACR 2019 includes over 30 abstracts building on QIAGEN’s Sample to Insight solutions to advance understanding of cancer and commitment to improve outcomes
Developing new automation options for QuantiFERON®-TB Gold Plus – the modern blood-based test for TB detection – and new QFT Access for high burden, low-resource regions
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like QIAGEN N.V. (NYSE:QGEN), with a market cap of US$9.0b, are often out of the spotlight.Read More...
QIAGEN (QGEN) believes that the partnership will aid in improvising the automation of pre-analytic manual steps, leading to its QuantiFERON-TB Gold Plus test.
Non-exclusive collaboration aims to accelerate adoption and ease of use in processing single-tube sample collection version of the market-leading modern blood test for latent TB de
QIAGEN N.V. announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2018, with the U.S.
In December 2018, QIAGEN N.V. (NYSE:QGEN) announced its most recent earnings update, which indicated that the business experienced a major tailwind, more than doubling its earnings from the prior year.Read More...
The regulatory go-ahead for the Ion platform is likely to provide Intuitive Surgical (ISRG) a competitive edge in the minimally-invasive-care space.